151 related articles for article (PubMed ID: 20009528)
1. Autophagy, ferritin and iron chelation.
De Domenico I; Ward DM; Kaplan J
Autophagy; 2010 Jan; 6(1):157. PubMed ID: 20009528
[No Abstract] [Full Text] [Related]
2. Autophagy of HSP70 and chelation of lysosomal iron in a non-redox-active form.
Kurz T; Brunk UT
Autophagy; 2009 Jan; 5(1):93-5. PubMed ID: 18989099
[TBL] [Abstract][Full Text] [Related]
3. Specific iron chelators determine the route of ferritin degradation.
De Domenico I; Ward DM; Kaplan J
Blood; 2009 Nov; 114(20):4546-51. PubMed ID: 19671920
[TBL] [Abstract][Full Text] [Related]
4. Iron Dysregulation in Parkinson's Disease: Focused on the Autophagy-Lysosome Pathway.
Chen LL; Huang YJ; Cui JT; Song N; Xie J
ACS Chem Neurosci; 2019 Feb; 10(2):863-871. PubMed ID: 30590010
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal iron, iron chelation, and cell death.
Terman A; Kurz T
Antioxid Redox Signal; 2013 Mar; 18(8):888-98. PubMed ID: 22909065
[TBL] [Abstract][Full Text] [Related]
6. Ferritin-stimulated lipid peroxidation, lysosomal leak, and macroautophagy promote lysosomal "metastability" in primary hepatocytes determining in vitro cell survival.
Krenn MA; Schürz M; Teufl B; Uchida K; Eckl PM; Bresgen N
Free Radic Biol Med; 2015 Mar; 80():48-58. PubMed ID: 25532933
[TBL] [Abstract][Full Text] [Related]
7. Rapid release of iron from ferritin by siderophores.
Tidmarsh GF; Klebba PE; Rosenberg LT
J Inorg Biochem; 1983 Apr; 18(2):161-8. PubMed ID: 6222161
[TBL] [Abstract][Full Text] [Related]
8. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
9. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
10. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy for malaria.
Gordeuk VR; Thuma PE; Brittenham GM
Adv Exp Med Biol; 1994; 356():371-83. PubMed ID: 7887243
[No Abstract] [Full Text] [Related]
12. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome.
De Domenico I; Vaughn MB; Li L; Bagley D; Musci G; Ward DM; Kaplan J
EMBO J; 2006 Nov; 25(22):5396-404. PubMed ID: 17082767
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
14. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
15. Chelation of lysosomal iron protects against ionizing radiation.
Berndt C; Kurz T; Selenius M; Fernandes AP; Edgren MR; Brunk UT
Biochem J; 2010 Dec; 432(2):295-301. PubMed ID: 20846118
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation, angiogenesis and tumor therapy.
Linden T; Wenger RH
Int J Cancer; 2003 Sep; 106(3):458-9. PubMed ID: 12845689
[No Abstract] [Full Text] [Related]
17. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
18. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
19. The cellular labile iron pool and intracellular ferritin in K562 cells.
Konijn AM; Glickstein H; Vaisman B; Meyron-Holtz EG; Slotki IN; Cabantchik ZI
Blood; 1999 Sep; 94(6):2128-34. PubMed ID: 10477743
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox--current knowledge and future challenges.
Porter JB
Ann N Y Acad Sci; 2010 Aug; 1202():87-93. PubMed ID: 20712778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
